Scharrer I - Search Results

1

Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.

Lusher JM, Scharrer I. Lusher JM, et al. Among authors: scharrer i. Int J Hematol. 2009 Nov;90(4):446-454. doi: 10.1007/s12185-009-0435-x. Epub 2009 Nov 3. Int J Hematol. 2009. PMID: 19882376 Review.

2

Experience with KOGENATE Bayer in surgical procedures.

Scharrer I; KOGENATE Bayer Study Group. Scharrer I, et al. Haemophilia. 2002 Mar;8 Suppl 2:15-8. doi: 10.1046/j.1351-8216.2001.00132.x. Haemophilia. 2002. PMID: 11966847

3

Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A.

Scharrer I, Brackmann HH, Sultan Y, Abshire T, Gazengel C, Ragni M, Gorina E, Vosburgh E, Kellermann E. Scharrer I, et al. Haemophilia. 2000 Nov;6(6):614-8. doi: 10.1046/j.1365-2516.2000.00432.x. Haemophilia. 2000. PMID: 11122384 Clinical Trial.

4

A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.

Aygören-Pürsün E, Scharrer I. Aygören-Pürsün E, et al. Among authors: scharrer i. Thromb Haemost. 1997 Nov;78(5):1352-6. Thromb Haemost. 1997. PMID: 9408018 Clinical Trial.

5

Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.

Scharrer I, Ehrlich HJ. Scharrer I, et al. Haemophilia. 2001 Jul;7(4):346-8. doi: 10.1046/j.1365-2516.2001.00515.x. Haemophilia. 2001. PMID: 11442637 Review.

6

Two years' experience with two recombinant factor VIII concentrates.

Brackmann HH, Aygören E, Scharrer I, Schwaab R, Hammerstein U, Oldenburg J. Brackmann HH, et al. Among authors: scharrer i. Blood Coagul Fibrinolysis. 1993 Jun;4(3):421-4. doi: 10.1097/00001721-199306000-00004. Blood Coagul Fibrinolysis. 1993. PMID: 8329567

7

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.

Scharrer I, Bray GL, Neutzling O. Scharrer I, et al. Haemophilia. 1999 May;5(3):145-54. doi: 10.1046/j.1365-2516.1999.00300.x. Haemophilia. 1999. PMID: 10444280 Review.

8

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.

Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E. Abshire TC, et al. Among authors: scharrer i. Thromb Haemost. 2000 Jun;83(6):811-6. Thromb Haemost. 2000. PMID: 10896230 Clinical Trial.

9

Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy.

Scharrer I, Neutzling O, Schwaab R, Oldenburg J, Ehrlich H. Scharrer I, et al. Ann Hematol. 1998;76 Suppl 1:A1-6. Ann Hematol. 1998. PMID: 9542469 Review. No abstract available.

10

Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven): a single centre experience.

Habermann B, Hochmuth K, Hovy L, Scharrer I, Kurth AH. Habermann B, et al. Among authors: scharrer i. Haemophilia. 2004 Nov;10(6):705-12. doi: 10.1111/j.1365-2516.2004.01037.x. Haemophilia. 2004. PMID: 15569165

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

238 results

Search Page

Filters